Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Camzyos
|
| gptkbp:chemical_formula |
C22 H28 N2 O4 S
|
| gptkbp:clinical_trial |
Phase 3
EXPLORER-HCM VALOR-HCM |
| gptkbp:clinical_use |
chronic management of HCM
|
| gptkbp:contraindication |
severe aortic stenosis
hypersensitivity to mavacamten concomitant use with strong CYP3 A inhibitors |
| gptkbp:developed_by |
gptkb:Myokardia
|
| gptkbp:dosage_form |
oral tablet
|
| gptkbp:effective_date |
gptkb:2022
April 2022 |
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mavacamten
|
| gptkbp:indication |
hypertrophic cardiomyopathy
obstructive hypertrophic cardiomyopathy |
| gptkbp:ingredients |
mavacamten
|
| gptkbp:invention |
gptkb:Myokardia
|
| gptkbp:lifespan |
approximately 15 hours
|
| gptkbp:marketed_as |
Camzyos
|
| gptkbp:mechanism_of_action |
myosin inhibitor
|
| gptkbp:metabolism |
gptkb:CYP3_A4
|
| gptkbp:pharmacokinetics |
highly protein-bound
|
| gptkbp:research_areas |
cardiovascular diseases
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety |
Pharmacology
Adverse Reactions Drug Interactions Clinical Studies Mechanism of Action Boxed Warning Dosage and Administration Patient Counseling Information Storage and Handling Use in Specific Populations Warnings and Precautions |
| gptkbp:side_effect |
dizziness
fatigue nausea hypotension bradycardia |
| gptkbp:targets |
cardiac myosin
|
| gptkbp:used_for |
hypertrophic cardiomyopathy
|
| gptkbp:bfsParent |
gptkb:Myokardia
|
| gptkbp:bfsLayer |
5
|